title: Leukocyte angiotensin II levels inpatients with essential hypertension:relation to insulin resistance.
abstract: Insulin resistance is involved in the pathogenesis of type 2 diabetes, hypertension, and atherosclerosis. Angiotensin (Ang) converting enzyme inhibitors and Ang II type 1 receptor antagonists improve insulin resistance in patients with essential hypertension, which suggest that tissue Ang II is involved in insulin resistance in patients with hypertension. To investigate the participation of tissue Ang II in insulin resistance associated with hypertension, we evaluated the Ang II-generating system in leukocytes and its relation to insulin resistance in patients with essential hypertension. Eighteen patients with essential hypertension participated in this study. Ang II was separated from leukocytes by reversed-phase high-performance liquid chromatography and measured by radioimmunoassay. Insulin resistance was evaluated by determining the steady-state of plasma glucose (SSPG) concentration. The Ang I- and Ang II-generating activities were evaluated in human leukocytes. Human leukocytes have Ang I- and Ang II-generating activities. The Ang II-generating activity was significantly inhibited by pepstatin A. Leukocyte Ang II level does not correlate with BP or plasma Ang II level in patients with essential hypertension. Leukocyte Ang II level strongly correlates with SSPG concentration, and significantly correlates with body mass index and plasma insulin, and with leptin levels in patients with essential hypertension. Leukocyte Ang II may be directly associated with insulin resistance.
authors.affiliation: Second Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan. ukudan@med.nihon-u.ac.jp
authors.forename: Noboru
authors.initials: N
authors.lastname: Fukuda
authors.forename: Mari
authors.initials: M
authors.lastname: Nakayama
authors.forename: Teng
authors.initials: T
authors.lastname: Jian
authors.forename: Chikara
authors.initials: C
authors.lastname: Satoh
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Nakayama
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Soma
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Izumi
authors.forename: Katsuo
authors.initials: K
authors.lastname: Kanmatsuse
mesh_terms: D000328:Adult; D000368:Aged; D000803:Angiotensin I / Q000097:blood; D000804:Angiotensin II / Q000097:blood*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure; D015992:Body Mass Index; D002851:Chromatography, High Pressure Liquid; D017315:Cilazapril / Q000627:therapeutic use; D005260:Female; D006706:Homeostasis; D006801:Humans; D006973:Hypertension / Q000473:pathology / Q000503:physiopathology*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D020738:Leptin / Q000097:blood; D007962:Leukocytes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; D000804:Angiotensin II; D017315:Cilazapril; D000803:Angiotensin I